Pages that link to "Q33441170"
Jump to navigation
Jump to search
The following pages link to Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study (Q33441170):
Displaying 30 items.
- Cabozantinib in the treatment of hepatocellular carcinoma. (Q38658285) (← links)
- Cabozantinib for the treatment of kidney cancer (Q38668871) (← links)
- Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy (Q41547474) (← links)
- A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma (Q47143379) (← links)
- An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma (Q47954829) (← links)
- Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma (Q49953442) (← links)
- Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. (Q52583955) (← links)
- Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. (Q54977952) (← links)
- Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. (Q55223567) (← links)
- The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells. (Q55437410) (← links)
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma (Q56373211) (← links)
- Systemic treatment for hepatocellular carcinoma (Q57074295) (← links)
- Molecular therapies and precision medicine for hepatocellular carcinoma (Q57143856) (← links)
- Systemic treatments for hepatocellular carcinoma: challenges and future perspectives (Q57301434) (← links)
- Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI) (Q57484611) (← links)
- The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma (Q58797003) (← links)
- Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein (Q59125907) (← links)
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (Q59150373) (← links)
- Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study) (Q59795984) (← links)
- Second-line treatment options in hepatocellular carcinoma (Q64058271) (← links)
- Cabozantinib for advanced hepatocellular carcinoma (Q64092687) (← links)
- Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma (Q89057713) (← links)
- 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations (Q89558091) (← links)
- Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression (Q89890361) (← links)
- New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma (Q92344153) (← links)
- Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma (Q92625988) (← links)
- Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma (Q92669216) (← links)
- Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma (Q92675371) (← links)
- Current options and future possibilities for the systemic treatment of hepatocellular carcinoma (Q93063612) (← links)
- Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors (Q94543854) (← links)